Blue test tubes arranged in a line, disappearing into the background

Drug news

NICE recommends Forxiga (BMS/AstraZeneca) for combination in Type 2 Diabetes

Read time: 1 mins

Last updated:27th Jun 2013

Published:27th Jun 2013

Source: Pharmawand

NICE. the National Institute of Health and Care Excellence has varied its earlier recommendation made in February and now recommends the use of the the SGLT 2 inhibitor Forxiga (dapagliflozin) from BMS and AstraZeneca as a dual therapy in combination with metformin (if it is used as described for DPP4-inhibitors) or in combination with insulin.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

self-amplifying mRNA COVID-19 vaccine demonstrates superior immune response compared with mRNA vaccine at 12 months post-vaccination

CSL and Arcturus Therapeutics announce the results of a head-to-head study demonstrating that self-amplifying (sa-mRNA) COVID-19 vaccine maintained superior immunogenicity compared to the conventional mRNA vaccine Comirnaty for up to one year against Wuhan-Hu-1, Omicron BA.4-5 and certain other variants, and at one-sixth the dose of the comparator (5 ug vs 30 ug, respectively)

1 mins

Drug news

enhertu granted priority review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy

AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting based on the positive results from the DESTINY-Breast06 Phase III trial which compared Enhertu to chemotherapy

1 min

Drug news

Biohaven achieves positive topline results in pivotal study of troriluzole in spinocerebellar ataxia

Biohaven Ltd. announces positive topline results from pivotal Study BHV4157-206-RWE (NCT06529146) demonstrating the efficacy of troriluzole on the mean change from baseline in the f-SARA after 3 years of treatment. The study achieved the primary endpoint and showed statistically significant improvements on the f-SARA at years 1 and 2

1 min

See all news